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Iberoamerican Pharmacometrics Network Congress 2018 
Report: Fostering Modeling and Simulation Approaches 
for Drug Development and Regulatory and Clinical 
Applications in Latin America 
Manuel Ibarra1, Teresa Dalla Costa2, Paula Schaiquevich3,4, Rodrigo Cristofoletti5,6, Ignacio Hernández González7, Nicte S. Fajardo-
Robledo8, Marcela Aragón Novoa9, Marisín Pecchio10, Ignacio Cortinez11, Iñaki F. Trocóniz12,13 and Elba M. Romero-Tejeda8,*
This report provides a brief description of the 2018 Red 
Iberoamericana de Farmacometría (RedIF) Congress 
that took place in Guadalajara (Mexico) on November 7–9, 
2018.  The meeting aimed to foster modeling and simu­
lation (M&S) approaches for drug development, regula­
tory sciences, and clinical application in Latin America. 
The organizations that cosponsored the meeting were 
the following: University of Guadalajara, International 
Society of Pharmacometrics (ISoP), International 
Pharmaceutical Federation (FIP), Clinic of Chronic 
Diseases and Special Procedures (CECyPE), Zurich 
Pharma, Pharmet (Pharmometrica), Lixoft, and ICON.
IBEROAMERICAN PHARMACOMETRICS NETWORK
Pharmacometrics and systems pharmacology have emerged 
in the developed world and were established as new para-
digms in drug discovery and development. Model- informed 
decisions are proved to reduce economic costs and favor 
ethics, focusing on optimizing clinical trial designs as well as 
on extracting the meaningful and relevant information from 
the data, far beyond statistically significant P  values.1–4 The 
application of this quantitative framework for dose optimiza-
tion and therapeutic innovation is on its way to change the 
rationale in which drugs are used in the clinical setting. As 
stated before by Pillai et al.,5 for the developing world these 
approaches represent an “opportunity to bring modern meth-
ods into play” and thus push forward the development of 
drugs, therapeutic strategies, and basic research in pharma-
cology and pharmaceutical innovation in our countries. The 
implementation, standardization, and acceptance of these 
disciplines entail an effort that should be concertedly per-
formed by means of scientific exchange and collaboration 
between all stakeholders.
In this context, the RedIF was founded in 2017 as the 
natural association of research groups from Argentina, 
Brazil, Chile, Colombia, Cuba, Mexico, Panama, Spain, and 
Uruguay. The main interest of this network is the promotion 
and advancement of pharmacometrics in Latin America, 
creating a multidisciplinary framework aimed to (i) support 
the learning process about the development of mechanis-
tic population pharmacokinetic/pharmacodynamic (PK/PD) 
models, (ii) promote and spread the use of pharmacometrics 
in Latin America, (iii) promote multicenter population- based 
PK/PD and disease progression studies in Latin America 
and the interchange of scientists across country members, 
(iv) create a database about the Latin American population 
to help researchers in meta- analysis studies and therapeu-
tic drug monitoring, and (v) harmonize nonclinical and clin-
ical practices to facilitate the exchange of information to 
fulfill registration requirements of new medications in Latin 
America.
THE PRESENTATIONS
The Chairs of the meeting, Mr Jaime Gutiérrez Chávez 
(Mexico) and Dr Iñaki F. Trocóniz (Universidad de Navarra, 
Spain) welcomed the audience and speakers and opened 
the meeting. A total of 125 scientists from academia, indus-
try, and regulatory agencies from 12 countries attended the 
meeting.
The first keynote lecture was delivered by Dr Iñaki F. 
Trocóniz (Universidad de Navarra, Spain), who addressed 
the role of quantitative systems pharmacology to under-
stand and hit the target of complex diseases. He focused 
on the Model-Informed Drug Discovery and Development 
(MID3) approach to guide dosage optimization, empha-
sizing the importance of moving from simply operating 
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in silico tools toward comprehensive data analysis and 
interpretation.
The Plenary Session 1 was dedicated to “Therapeutic 
Drug Monitoring.” Dr Paula Schaiquevich (Hosptial de 
Pediatría JP Garrahan, Argentina) highlighted the im-
portance of considering not only PK but also PD vari-
ability when applying therapeutic drug monitoring in 
pediatrics. The key role of prior knowledge, in terms of 
quality and abundance, was also addressed. Dr Michael 
Neely (Children’s Hospital Los Angeles, United States 
(US)) presented a nonparametric approach for individual-
ized therapy and several examples providing the routine 
monitoring of patients using this tool. He also provided 
the basis for multiple- model optimal as a new sampling 
strategy that requires minimal computation while having 
distinct advantages when compared with existing ap-
proaches. Dr Silvia Romano (Universidad Autónoma de 
San Luis Potosí, Mexico) spoke about several local ini-
tiatives on therapy individualization. She pointed out the 
relevance of clinical testing for constitutional pharmacog-
enetic variants implicated in interindividual drug response 
variability as an important guide for dosing adjustments.
By the end of this session, Dr Manuel Ibarra (Universidad 
de la República, Uruguay) presented the mission (“to pro-
mote the advancement of pharmacometrics in Latin America 
through its application in pharmacological research, en-
hancing drug development and introduction of therapeutic 
strategies as well as in the clinical setting supporting dose 
optimization and rational use of medicines. Additionally, we 
aim to create a multidisciplinary framework for education 
and training of scientists getting into this discipline”) and 
vision (“to become a recognized Iberoamerican network in 
the field of pharmacometrics by the promotion of education 
and training of personnel in this area and the encourage-
ment of its application in the fields of development, regis-
tration, and use of medicines, while integrating academia, 
industry, regulatory, and clinic sectors”) of the RedIF, which 
contains, so far, representatives from nine countries.
The Plenary Session 2 was about “PK/PD Modeling.” 
Dr Stephan Schmidt (University of Florida, US), who briefly 
reviewed the evolution of M&S, also discussed the im-
portance of moving toward concrete applications of the 
learn- confirm paradigm. He presented two successful case 
studies in which integrative M&S approaches guided clin-
ical (dosing adjustment) and regulatory decision making 
(investigation of purported therapeutic inequivalence after 
replacing brand name by generic formulations). Dr Marc 
Lavielle (Inria and Ecole Polytechnique, France) presented 
new methods, algorithms, and tools for model building 
and model assessment included in the R package Rslmx 
(“R speaks Monolix”).6 He ran real- time modeling for war-
farin PK to illustrate the advantages of using an automatic 
iterative procedure to accelerate and optimize the process 
of model building (Stochastic Approximation for Model 
Building Algorithm). Lastly, Dr Bibiana Araujo (Universidade 
Federal do Rio Grande do Sul, Brazil) exemplified the influ-
ence of disease states on drug tissue distribution. She ex-
plained the basis of microdialysis and the use of it to assess 
the impact of cryptococcal meningitis on drug penetration 
through the blood–brain barrier, emphasizing the need to 
consider disease progression when investigating the neces-
sity of dosage optimization.
The second keynote lecture was delivered by Dr Hartmut 
Derendorf (Distinguished Professor, University of Florida, 
US), who spoke about applying M&S for dose optimization 
on Earth and in space. He started his presentation showing 
the economic issues surrounding drug development and the 
potential for applying quantitative modeling approaches. He 
reviewed the development of microdialysis to assess drug 
tissue distribution, highlighting the scientific contribution of 
Iberoamerican scientists. He also highlighted the limitations 
of static metrics for PD (e.g., minimum inhibitory concentra-
tion) for antimicrobials and the usefulness of metrics char-
acterizing the time course of PD response (e.g., kill curves). 
Finally, he discussed how simulated microgravity does not 
seem to affect disposition of antimicrobial drugs using cip-
rofloxacin as a case study.
The Plenary Session 3 was titled “Virtual Bioequivalence 
(BE).” Dr Rodrigo Cristofoletti (Anvisa, Brazil) reviewed the 
average BE paradigm, highlighting that it is not a scientific 
fact per se but a judgment (i.e., relying on facts, beliefs, and 
assumptions but also prone to biases). He spoke about the 
importance of predictive in vitro dissolution tests to gen-
erate reliable inputs for the mechanistic absorption mod-
els; otherwise, virtual BE trials may lead to false negative 
or false positive results. He also noted that commercially 
available, physiologically based pharmacokinetic (PBPK) 
software do not account for interoccasion variability, and 
further developments are still needed to create a virtual BE 
platform. Dr José Trinidad Urízar (Universidad Autónoma 
de San Luis Potosí, Mexico) pointed out the lack of a clear 
and harmonized definition of virtual BE. He also stressed 
the requirement of high- quality information to parameter-
ize the system component of the PBPK model and high-
lighted some critical knowledge gaps. He also spoke 
about other applications of PBPK models in drug devel-
opment, including drug–drug interactions. Dr Elba Romero 
Tejeda (Universidad de Guadalajara, Mexico) discussed 
formulation- related issues leading to failures in the demon-
stration of BE among brand names and generics. She 
raised a thought- provoking question (i.e., are we ready for 
virtual BE?), contrasting the rapid scientific progress and 
the slow regulatory process. She mentioned the relevance 
of RedIF as an independent and neutral board to moderate 
the dialogue among different stakeholders involved in drug 
development in Latin America.
The Plenary Session 4 was dedicated to “Translational 
PBPK/PD.” Dr Mirjam Trame (Novartis, US) briefly re-
viewed the historical development of PBPK models since 
the pioneer work of Torsten Theorel to today, highlighting 
its main applications. She presented a successful case 
study using global metabolomics biomarkers to guide in-
terspecies scaling. She also discussed the importance of 
verifying whether the model is able to predict prior clinical 
knowledge before exploring what if scenarios. Dr Leyanis 
Rodríguez Vera (Universidad de Havana, Cuba) applied 
population PK to optimize nimotuzumab dosage regimens 
in patients with advanced breast cancer. Further investi-
gations about the PK/PD relationships should be consid-
ered to decide whether PK changes are indeed clinically 
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relevant. Dr Teresa Dalla Costa (Universidade Federal do 
Rio Grande do Sul, Brazil) was the last speaker of this ses-
sion. She presented a translational study to determine the 
efficacious cefazolin prophylactic dose for bariatric sur-
gery using free subcutaneous concentrations accessed by 
microdialysis. She reinforced the necessity of considering 
tissue-free concentrations as well as PD biomarkers, e.g., 
minimum inhibitory concentration, to investigate potential 
prophylactic effective doses.
The third keynote lecture was delivered by Dr Mats 
Karlsson (Uppsala University, Sweden), who spoke about 
extensive model assessment through model–proxy analy-
ses. His talk focused on a diagnostic tool to quantitatively 
identify model misspecifications and rectifying actions. 
He showed how model- based postprocessing of routinely 
used diagnostics such as conditional weighted residuals 
may be valuable for residual unexplained variability model 
identification during model development and evaluation.7
The Plenary Session 5 was dedicated to “Drug Disease 
Modeling.” Dr María García- Cremades Mira (University of 
California San Francisco, US) presented a case study using 
a disease progression model to investigate the efficacy of 
tenofovir in HIV prophylaxis and the risk factors associ-
ated with HIV transmission. She emphasized that disease 
progression may affect both PK and PD components and 
thus should be considered when addressing drug efficacy 
and safety. Dr José Rodrigo González Martínez (Centro 
de Investigación y de Estudios Avanzados del Instituto 
Politécnico Nacional, Mexico) spoke about compensatory 
homeostatic mechanisms in hypertension therapy and how 
the clinical outcome may not directly relate to the plasma 
drug concentration. He also pointed out the challenges re-
lated to dosing adjustment in case of critically ill patients. In 
this case, it would be relevant to consider covariates related 
to pathophysiologic status and therapeutic measures using 
a Bayesian- like approach.
In addition, three poster sessions, including 38 pre-
sentations and six oral communications were held during 
the meeting. Furthermore, prior to the meeting, 2- day 
hands- on workshops on Monolix (presented by Dr Marc 
Levielle) and NONMEM (presented by Dr Iñaki Trocóniz 
and Dr Manuel Ibarra) as well as a postcongress workshop 
on nlmixr (presented by Dr Mirjam Trame) completed the 
scientific program that altogether consisted of 64 attend-
ees, among PhD students, senior academics, regulators, 
and industrial scientists. Following the RedIF educational 
philosophy, the precongress workshops were given in 
Spanish.
Altogether, Figure 1 summarizes the topics covered 
during the congress.
Pharmacometrics and Quantitative Systems Pharma-
cology concepts are still emerging in Latin America. Just a 
few experienced research groups, whose academic train-
ing was done in traditional M&S centers abroad, have been 
struggling to spread state- of- the- art concepts and applica-
tions of M&S in their countries. No formalized M&S curricula 
have been implemented nor has guidance on PBPK or pop-
ulation PK modeling been issued by regulatory authorities in 
Latin America yet. In this context, the 2018 RedIF Congress 
created a platform for academicians, industrial scientists, 
and regulators to exchange their latest research, discuss 
challenges, set new collaborations, and foster M&S- based 
approaches for drug development, including regulatory and 
clinical applications throughout Latin America.
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Figure 1 Different topics under the umbrella of the Pharma-
cometrics discipline covered during the 2018 Red Iberoa-
mericana de Farmacometría (RedIF) Congress in Guadalajara 
(México). The graphic also shows the distribution the distribution 
per topic of speakers who are RedIF members. PBPK, 
Physiologically Based Pharmacokinetic; PK, Pharmacokinetic; 
PKPD, Pharmacokinetic and Pharmacodynamic. 
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